One study led and coordinated by the Academic Research Organization (ARO), Hospital Israelita Albert Einstein, in partnership with Pfizer, revealed this Wednesday, 16, that the drug tofacitinib showed positive results to reduce by 37% the risk of death and respiratory failure in patients hospitalized because of covid-19.
Tofacitinib belongs to the category of Janus Kinase Inhibitors (JAKs), proteins involved in triggering inflammatory diseases, and is currently indicated for the treatment of rheumatoid arthritis, psoriatic arthritis and ulcerative colitis.
In the case of covid-19, its action would reduce the risk of occurrence of the so-called inflammatory storm, a serious complication of the disease associated with the exacerbated response of the immune system to the entry of SARS-CoV-2.
“The results of the clinical trial were positive, showing that the drug can act in the recovery of patients with covid-19”, says Márjori Dulcine, medical director of Pfizer Brasil.
The survey conducted on a group of 289 adult patients admitted to 15 treatment centers spread across the country. The results showed a lower incidence of death or respiratory failure due to the new coronavirus among patients who received the drug (18.1%) compared to those who received the placebo (29.0%). Participants were observed for a period of 28 days.
However, it is important to note that the drug has not been approved or authorized for use by any regulatory agency in the world for the treatment of covid-19, as the study now published is the first to assess its impact on the treatment of the disease. It is a medicine of high value and that is made available by the SUS. In pharmacies it is found for prices above R$ 5 thousand.